# Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)

> **NCT03455439** · — · COMPLETED · sponsor: **Bayer** · enrollment: 552 (actual)

## Conditions studied

- Heart Failure

## Interventions

- **DRUG:** Rivaroxaban (Xarelto, BAY59-7939)

## Key facts

- **NCT ID:** NCT03455439
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-16
- **Primary completion:** 2021-07-17
- **Final completion:** 2022-01-11
- **Target enrollment:** 552 (ACTUAL)
- **Last updated:** 2023-11-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03455439

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03455439, "Risk Factors of Outcomes Associated With Disease Progression in Patients With Atrial Fibrillation and Heart Failure (HF) Who Are Receiving a Direct Oral Anticoagulant (Rivaroxaban)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03455439. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*